Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Convention Name October 31, 2024 8:30 AM ET
Firm Contributors
Justine Koenigsberg – VP, IRNello Mainolfi – Founder, President & CEOJared Gollob – Chief Medical OfficerBruce Jacobs – CFO
Convention Name Contributors
Marc Frahm – TD CowenKalpit Patel – B. RileyAlexei Siniakov – Truist SecuritiesBrad Canino – Stifel NicolausGospel Enyindah-Asonye – Morgan StanleyKelly Shi – JefferiesJeff Jones – OppenheimerEric Joseph – J.P. MorganMichael Schmidt – Guggenheim SecuritiesFaisal Khurshid – Leerink Companions
Operator
Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Outcomes Convention Name. All individuals shall be in listen-only mode. [Operator Instructions] After the immediately’s presentation, there shall be a possibility to ask questions. [Operator Instructions] Please notice this occasion is being recorded.
I would really like now to show the convention over to Justine Koenigsberg, Head of Investor Relations. Please go forward.
Justine Koenigsberg
Thanks. Good morning, and welcome to Kymera’s quarterly replace name. Becoming a member of me this morning are Nello Mainolfi, Founder, President and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, our Chief Monetary Officer. Please notice that in Jared’s remarks, we intend to reference knowledge from slides in our company presentation, which is on the market inside the IR part of our web site at kymeratx.com. Following our ready remarks, we are going to open the decision to questions. We ask that you simply please restrict your questions to at least one and a related follow-up to guarantee we’ve sufficient time to handle everybody’s questions.
Earlier than we start, I want to remind you that immediately’s dialogue will embody forward-looking statements about our future expectations, plans and prospects. These statements are topic to dangers and uncertainties that will trigger precise outcomes to vary materially from these projected. An outline of those dangers might be
